Delegates are getting ready to descend on Madrid for an eagerly-anticipated European Society for Medical Oncology congress Sept.8-12 and among the deluge of data, most eyes will be on AstraZeneca PLC and results from trials of two drugs key to the firm's future success in lung cancer - Imfinzi (durvalumab) and Tagrisso (osimertinib).
Most keenly-watched will be the results from the PACIFIC trial of Imfinzi, AstraZeneca's PD-1/L1 inhibitor, in unresectable stage III non-small cell lung cancer (NSCLC)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?